[Clinical experience with a new spironolactone-thiabuzide combination].
D000368:Aged; D001835:Body Weight; D004077:Digoxin / Q000627:therapeutic use; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D004487:Edema / Q000188:drug therapy*; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006029:Glycosuria; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009318:Natriuresis; D011188:Potassium / Q000652:urine; D013148:Spironolactone / Q000009:adverse effects / Q000627:therapeutic use*; D013328:Strophanthins / Q000627:therapeutic use; D014044:Tolbutamide / Q000627:therapeutic use
D004232:Diuretics; D013328:Strophanthins; D013148:Spironolactone; D004077:Digoxin; D005665:Furosemide; D014044:Tolbutamide; D011188:Potassium
Klinische Erfahrungen mit einer neuen Spironolacton- Thiabutazid-Kombination.